Morgan Stanley
AVDL

Morgan Stanley’s Avadel Pharmaceuticals AVDL Stock Holding History

Morgan Stanley’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-529,074
Closed -$11.4M – 8302
2025
Q4 		$11.4M Sell
529,074
-1,729,609
-77% -$33.6M ﹤0.01% 3497
2025
Q3 		$34.5M Buy
2,258,683
+1,066,077
+89% +$13.9M ﹤0.01% 2351
2025
Q2 		$10.6M Buy
1,192,606
+157,992
+15% +$1.39M ﹤0.01% 3392
2025
Q1 		$8.1M Sell
1,034,614
-174,782
-14% -$1.46M ﹤0.01% 3532
2024
Q4 		$12.7M Buy
1,209,396
+260,992
+28% +$3.17M ﹤0.01% 3186
2024
Q3 		$12.4M Buy
948,404
+115,092
+14% +$1.75M ﹤0.01% 3254
2024
Q2 		$11.7M Buy
833,312
+167,901
+25% +$2.74M ﹤0.01% 3195
2024
Q1 		$11.2M Sell
665,411
-1,318,583
-66% -$19.6M ﹤0.01% 3256
2023
Q4 		$28M Buy
1,983,994
+1,546,938
+354% +$18.2M ﹤0.01% 3044
2023
Q3 		$4.5M Sell
437,056
-24,038
-5% -$322K ﹤0.01% 3831
2023
Q2 		$7.6M Buy
461,094
+115,383
+33% +$1.5M ﹤0.01% 3432
2023
Q1 		$3.17M Sell
345,711
-1,609
-0.5% -$13.2K ﹤0.01% 4140
2022
Q4 		$2.49M Buy
347,320
+468
+0.1% +$3.28K ﹤0.01% 4317
2022
Q3 		$1.74M Buy
346,852
+30,491
+10% +$168K ﹤0.01% 4532
2022
Q2 		$772K Sell
316,361
-26,648
-8% -$109K ﹤0.01% 5184
2022
Q1 		$2.34M Sell
343,009
-114,255
-25% -$785K ﹤0.01% 4394
2021
Q4 		$3.69M Buy
457,264
+33,044
+8% +$302K ﹤0.01% 4035
2021
Q3 		$4.16M Buy
424,220
+47,955
+13% +$378K ﹤0.01% 3930
2021
Q2 		$2.53M Buy
376,265
+152,186
+68% +$1.21M ﹤0.01% 4455
2021
Q1 		$2.03M Buy
224,079
+5,774
+3% +$46.7K ﹤0.01% 4248
2020
Q4 		$1.46M Sell
218,305
-114,161
-34% -$714K ﹤0.01% 4413
2020
Q3 		$1.68M Buy
332,466
+189,550
+133% +$1.38M ﹤0.01% 3810
2020
Q2 		$1.16M Sell
142,916
-22,672
-14% -$200K ﹤0.01% 4061
2020
Q1 		$1.31M Sell
165,588
-563,701
-77% -$4.33M ﹤0.01% 3732
2019
Q4 		$5.51M Sell
729,289
-11,207
-2% -$59.2K ﹤0.01% 3103
2019
Q3 		$3.08M Buy
740,496
+22,595
+3% +$56.6K ﹤0.01% 3395
2019
Q2 		$2.08M Buy
717,901
+5,243
+0.7% +$9.01K ﹤0.01% 3744
2019
Q1 		$1.03M Sell
712,658
-9,361
-1% -$21.2K ﹤0.01% 4094
2018
Q4 		$1.86M Sell
722,019
-55,253
-7% -$188K ﹤0.01% 3832
2018
Q3 		$3.41M Buy
777,272
+295,036
+61% +$1.59M ﹤0.01% 3565
2018
Q2 		$2.96M Sell
482,236
-649,101
-57% -$4.55M ﹤0.01% 3709
2018
Q1 		$8.25M Sell
1,131,337
-429,402
-28% -$3.78M ﹤0.01% 2526
2017
Q4 		$12.8M Buy
1,560,739
+58,313
+4% +$547K ﹤0.01% 2145
2017
Q3 		$15.8M Sell
1,502,426
-69,071
-4% -$659K ﹤0.01% 1811
2017
Q2 		$17.3M Buy
1,571,497
+279,051
+22% +$2.8M 0.01% 1657
2017
Q1 		$12.5M Buy
1,292,446
+79,913
+7% +$799K ﹤0.01% 1987
2016
Q4 		$12.6M Buy
1,212,533
+109,039
+10% +$1.2M ﹤0.01% 2008
2016
Q3 		$13.7M Buy
1,103,494
+168,772
+18% +$2.21M ﹤0.01% 1755
2016
Q2 		$10M Buy
934,722
+145,834
+18% +$1.55M ﹤0.01% 1980
2016
Q1 		$8.71M Buy
788,888
+69,425
+10% +$690K ﹤0.01% 1980
2015
Q4 		$8.79M Buy
719,463
+408,531
+131% +$6.37M ﹤0.01% 2099
2015
Q3 		$5.07M Buy
310,932
+44,554
+17% +$981K ﹤0.01% 2647
2015
Q2 		$5.64M Buy
266,378
+160,429
+151% +$2.88M ﹤0.01% 2682
2015
Q1 		$1.91M Sell
105,949
-308,826
-74% -$4.84M ﹤0.01% 3623
2014
Q4 		$7.11M Sell
414,775
-26,113
-6% -$373K ﹤0.01% 2381
2014
Q3 		$6.31M Buy
440,888
+152,182
+53% +$2.19M ﹤0.01% 2437
2014
Q2 		$4.33M Sell
288,706
-68,065
-19% -$821K ﹤0.01% 2786
2014
Q1 		$4.78M Buy
356,771
+266,679
+296% +$2.86M ﹤0.01% 2620
2013
Q4 		$726K Sell
90,092
-19,038
-17% -$134K ﹤0.01% 4184
2013
Q3 		$717K Sell
109,130
-4,477
-4% -$27.5K ﹤0.01% 4073
2013
Q2 		$697K Buy
+113,607
New +$587K ﹤0.01% 4010

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Morgan Stanley's AVDL Position: Q1 2026 in Review

Morgan Stanley sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 529,074 shares — an estimated $11.4M sold.

Morgan Stanley first reported a position in AVDL in Q2 2013 and held it in 51 quarters. The position peaked at $34.5M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Morgan Stanley reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Morgan Stanley sold 529,074 Avadel Pharmaceuticals shares in Q1 2026, an estimated $11.4M.
  • Morgan Stanley first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 51 quarters.
  • Morgan Stanley's Avadel Pharmaceuticals position peaked at $34.5M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.